Alzheimer’s disease – Genomes to People

The Alzheimer’s Disease Neuroimaging Intitiative in the era of Alzheimer’s disease treatment: A review of ADNI studies from 2021 to 2022

Veitch DP, Weiner, MW, Miller M, Aisen PS, Ashford MA, Beckett LA, Green RC, Harvey D, Jack CR Jr., Jagust W, Landau SM, Morris JC, Nho KT, Nosheny R, Okonkwo O, Perrin RJ, Petersen RC, Rivera Mindt M, Saykin A, Shaw LM, Toga AW, Tosun D for the Alzheimer's Disease Neuroimaging Initiative

The Journal of the Alzheimer's Association August 2023

Public perspective on medications to delay Alzheimer’s disease symptoms

Rich MB, Blout Zawatsky CL, Botta JJ, Christensen KD

Journal of the National Society of Genetic Counselors March 2023

Robert C. Green: By sharing their genetic risks, Hemsworth, Jolie are raising awareness of testing

Chicago Tribune |

December 2022

G2P Blog

In this Chicago Tribune post, G2P Director Robert Green writes that Hemsworth and Jolie are accelerating awareness and acceptance of a future where we do not wait to respond to the ravages of so many diseases but rather anticipate, predict and prevent them through genomics.

Disclosing APOE genotype to individuals at risk for Alzheimer’s disease

Roberts JS, Green RC

Alzheimer's Disease International September 2021

Using the Alzheimer’s Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer’s disease

Veitch DP, Weiner MW, Aisen PS, Beckett LA, DeCarli C, Green RC, Harvey D, Jack CR, Jagust W, Landau SM, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Rivera-Mindt M, Saykin AJ, Shaw LM, Toga AW, Tosun D, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative

Alzheimer's & Dementia: The Journal of the Alzheimer's Association September 2021

How will Aducanumab approval impact Alzheimer’s disease research?

Weiner MW, Aisen PS, Beckett LA, Green RC, Jagust William, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Mindt MR, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ and the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Journal of Prevention of Alzheimer's Disease July 2021

Genome-wide association study of rate of cognitive decline in Alzheimer’s patients identifies novel genes and pathways

Sherva R, Gross A, Mukherjee S, Koesterer R, Amouyel P, Bellenguez C, Bennett D, Chibnik L, Cruchaga C, Farrer L, Kraft P, Mayeux R, Munsie L, Newhouse S, Saykin A, Schellenberg G, the Alzheimer’s Disease Genetics Consortium, Crane PK, Green RC

Alzheimer's & Dementia June 2020

Disclosing genetic risk of Alzheimer’s dementia to individuals with mild cognitive impairment

Christensen KD, Karlawish J, Roberts JS, Uhlmann WR, Harkins K, Wood EM, Obisesan TO, Le LQ, Cupples LA, Zoltick ES, Johnson MS, Bradbury MK, Waterston LB, Chen CA, Feldman S, Perry DL, Green RC

Alzheimer's & Dementia: Translational Research & Clinical Interventions March 2020

Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families

Cuenco KT, Friedland R, Baldwin CT, Guo J, Vardarajan B, Lunetta KL, Cupples LA, Green RC, DeCarli C, Farrer LA

Neurobiology of Aging February 2011

Genetic architecture of subcortical brain structures in 38,854 individuals worldwide

Satizabal CL, Adams HHH, Hibar DP, White CC, Stein JL, Scholz M, Sargurupremraj M, Jahanshad N, Smith AV, Bis JC, Jian X, Luciano M, Hofer E, Teumer A, Lee SJ, Yang J, Yanek LR, Lee TV, Li S, et al.

Nature Genetics October 2019

Bioethicists worried patients couldn’t handle their own genetic testing results. They were (mostly) wrong

STAT |

July 2019

Press

The first major randomized clinical trial on the effect of disclosing genetic information found that people who decided to learn about their genetic risk of developing Alzheimer’s disease did not experience large, negative psychological impacts.

Is ignorance really bliss when it comes to knowing your risk of Alzheimer’s? Medical experts are split

89.3 KPCC |

July 2019

Radio

Dr. Robert Green and Kreg Klugman explore the pros and cons of knowing one’s risk for developing Alzheimer’s.

MIT scientists try to fix Alzheimer’s risk gene by editing RNA

WBUR |

July 2019

Press

MIT scientists used a novel tool to try to edit out a genetic risk for Alzheimer’s disease, they report in the journal Science. Dr. Robert Green gives his opinion on the new technology.

Should you find out if you’re at risk of Alzheimer’s?

The Wall Street Journal |

July 2019

Press

Dr. Robert Green on learning of your genetic risk to developing Alzheimer’s quotes: “Not everything has a pill or medical-prevention plan, but many information-seeking persons can find all sorts of benefits in better understanding their risk of future disease.”

Diagnosis and Management of Alzheimer’s Disease and Other Dementias

Book

Robert C. Green

January 2005

Head circumference, atrophy and cognition: Implications for brain reserve in Alzheimer disease

Perneczky R, Wagenpfeil S, Lunetta KL, Cupples LA, Green RC, DeCarli C, Farrer LA, Kurz A

July 2010

Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates AB, tau, immunity and lipid processing

Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V… Green RC…Seshadri S, Williams J, Amouyel P, Schellenberg GD, Lambert J-C, Pericak-Vance MA

Nature Genetics March 2019

Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative

Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairens NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Peterson RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ

Alzheimer's & Dementia February 2019

Communication predictors of patient and companion satisfaction with Alzheimer’s genetic risk disclosure

Guan Y, Roter DL, Erby LH, Wolff JL, Gitlin LN, Roberts JS, Green RC, Christensen KD

Journal of Health Communication October 2018

Plenary presentation at the Advances in Genome Biology and Technology Precision Health Meeting

AGBT Precision Health Conference |

September 2018

Video

Dr. Robert C. Green speaks at the 2018 Advances in Genome Biology and Technology (AGBT) Precision Health Conference in San Diego, California about our efforts to gather empirical data on genome sequencing healthy individuals. Watch to learn more about G2P’s MilSeq, BabySeq, MedSeq, PeopleSeq, PGen and REVEAL projects. Click here for more on the conference.

Minding the aging brain: Are we ready for personalized medicine?

Karlawish J, Green RC.

American Journal of Psychiatry February 2014

The impact of genetic counselors’ use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer’s disease

Guan Y, Roter DL, Wolff JL, Gitlin LN, Christensen KD, Roberts JS, Green RC, Erby LH.

Patient Education and Counseling May 2018

Assembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping: the Alzheimer’s Disease Neuroimaging Initiative

Ridge PG, Wadsworth ME, Miller JB, Saykin AJ, Green RC, for the Alzheimer’s Disease Neuroimaging Inititiave, Kauwe JSK

Alzheimer's & Dementia April 2018

Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease

Nho K, Kim S, Horgusluoglu E, Risacher SL, Shen L, Kim D, Lee S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR, Weiner MW, Green RC, Toga AW, Saykin AJ for the Alzheimer’s Disease Neuroimaging Initiative

BMC Medical Genomics October 2017

A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone

Christensen KD, Uhlmann WR, Roberts JS, Linnenbringer E, Whitehouse PJ, Royal CDM, Obisesan TO, Cupples LA, Butson MB, Fasaye GA, Hiraki S, Chen CA, Siebert U, Cook-Deegan R, Green RC.

Genetics in Medicine July 2017

Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease

Sims R, van der Lee SJ, Naj AC...(232 authors)...Green RC...(215 authors)...Seshadri S, Williams J, Schellenberg GD.

Nature Genetics July 2017

G2P Newsletter May 2017

Genomes2People |

May 2017

G2P News

In spring, The New York Times highlighted G2P’s work with REVEAL-SCAN, team members participated in a 10k marathon to raise money for genetic research, and G2P researchers published a new article on direct-to-consumer testing.

New gene tests pose a threat to insurers

New York Times |

May 2017

Press

Dr. Green has found that people who learn they have the ApoE4 gene fare just as well if they get the results without counseling.those who learned they had the gene variant — Ms. Reilly was one of them — were nearly six times more likely to buy long-term care insurance than those who did not.

Disclosing genetic risk of Alzheimer’s disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study

Guan Y, Roter DL, Erby LH, Wolff JL, Gitlin LN, Roberts JS, Green RC, Christensen KD

Patient Education and Counseling May 2017

The Alzheimer’s Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Weiner MW, Veitch DP, Aisen PS, Becket LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Salazar J, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ

Alzheimer's & Dementia February 2017

Novel genetic loci associated with hippocampal volume

Hibar DP, Adams HH, Jahanshad N, Chauhan G, … Green RC, … Medland SE, Seshadri S, Thompson PM, Ikram MA

Nature Communication January 2017

Crowdsourced estimation of cognitive decline and resilience in Alzheimer’s disease

Allen GI, Amoroso N, Anghel C, Balagurusamy V, Bare CJ, Beaton D, Bellotti R, Bennett DA, Boehme K, Boutros PC, Caberlotto L, Caloian C, Campbell F, Neto EC, Chang Y-C, Chen B, Chen C-Y, Chien T-Y, Clark T, Das S, Davatzikos C, Deng J, Dillenberger D, Dobson RJB, Don Q, Doshi J, Duma D, Errico R, Erus G, Everett E, Fardo DW, Friend SH, Fröhlich H, Gan J, St. George-Hyslop P, Ghosh SS, Glaab E, Green RC, Guan Y, Hong M-Y, Huang C, Hwang J, Ibrahim J, Inglese P, Jiang Q, Katsumata Y, Kauwe JSK et al.

Alzheimer's & Dementia May 2016

Genomes2People: a roadmap for genomic medicine

Front Line Genomics |

May 2016

Press

An overview and summary of the main projects that are being conducted within the G2P program, both past and present. This article also includes the progract managers and research assistants on each major project.

Global and local ancestry in African Americans: Implications for Alzheimer’s disease risk

Hohman TJ, Cooke-Bailey JN, Reitz C, Jun G, Naj A, Beecham GW, Liu Z, Carney RM, Vance JM, Cuccaro ML, Rajbhandary R, Vardarajan BN, Wang L-S, Valladares O, Lin C-F, Larson EB, Graff-Radford NR, Evans D, De Jager PL, Crane PK, Buxbaum JD, Murrell JR, Raj T, Ertekin-Taner N, Logue MW, Baldwin CT, Green RC, Barnes LL, Cantwell LB, Fallin MD, Go RCP, Griffith P, Obisesan TO, Manly JJ, Lunetta KL, Kamboh MI, Lopez OL, Bennett DA, Hardy J, Hendrie HC, Hall KS, Goate AM, Lang R, Byrd GS, Kukull WA, Foroud TM, Farrer LA, Martin ER, Pericak-Vance MA, Schellenberg GD, Mayeux R, Haines JL, Thornton-Wells TA

Alzheimer's & Dementia March 2016

Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer’s disease

Nho K, Horgusluoglu E, Kim S, Risacher SL, Kim D, Foroud T, Aisen PS, Petersen RC, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toba AW, Saykin AJ and the Alzheimer’s Disease Neuroimaging Initiative

BMC Medical Genomics February 2016

The executive prominent/memory prominent spectrum of Alzheimers disease is highly heritable

Mez J, Mukherjee S, Thornton T, Fardo DW, Trittschuh E, Sutti S, Sherva R, Kauwe JS, Jaz AC, Beecham GW, Gross A, Saykin AJ, Green RC, Crane PK.

Neurobiology of Aging February 2016

More information on genetic risks is actually reassuring, study finds

Boston Globe |

February 2016

Press

Within the REVEAL-SCAN study, one group of participants are given back the results on Alzheimer’s and additional heart disease information. Patients who are receiving the additional information are finding it reassuring that they can take measures to prevent at least one of their possible conditions if they have mutations for both.

Disclosing pleiotropic effects during genetic risk assessment for Alzheimer’s Disease: A randomized trial

Christensen KD, Roberts JS, Whitehouse PJ, Royal CDM, Obisesan TO, Cupples LA, Vernarelli JA, Bhatt DL, Linnenbringer E, Butson MB, Fasaye G-A, Uhlmann WR, Hiraki S, Cook-Deegan R, Green RC, for the REVEAL Study Group.

Annals of Internal Medicine February 2016

No worries! CAD risk disclosure OK at Alzheimer’s genotyping

Medscape |

January 2016

Press

Through the REVEAL study, researchers were testing to see how participants anxiety, depression, and test-related distress would be affected by knowing their genetic results of Alzheimer’s Disease and Coronary artery disease.

Disclosure of incidental genetic findings can have positive impact for patients

Brigham Women's Hospital |

January 2016

Press Release

A new study has found that providing unanticipated information about risk of coronary artery disease during a genetic risk assessment for Alzheimer’s disease helped some participants cope with their results, and also motivated participants to make changes to their health behaviors. The results of the randomized controlled study are published online in the journal Annals of … Continued

Alzheimer's disease

Latest News From Genomes2People